Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature`s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Website: omegatherapeutics.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (66.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -1 063.7% (LTM)
  • Share price is 32.5% higher than minimum and 98.5% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: OMGA
Share price, USD:  (0.0%)0.1426
year average price 0.1440  


year start price 0.1943 2025-02-14

max close price 0.2298 2025-02-15

min close price 0.1426 2025-02-24

current price 0.1426 2026-02-13
Common stocks: 32 303 540

Dividend Yield:  0.0%
EV / Sales: 12.8x
Margin (EBITDA LTM / Revenue): -875.0%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 5
Net Debt ($m): 98
EV (Enterprise Value): 103
EBITDA LTM (млн $): -70
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-08-18newsfilecorp.com

Omega Pacific Closes First Tranche of Offering

2024-12-04accesswire.com

Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property

2024-11-19accesswire.com

Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property

2024-11-12accesswire.com

Omega Pacific Earns 51% Interest in Williams Property

2024-11-05accesswire.com

Omega Pacific Adds John Williamson as Independent Director

2024-10-28accesswire.com

Omega Pacific Extends Historical Hole WM22-02 Mineralization to 2.16 G/t Au Over 96.92 Metres

2024-09-18accesswire.com

Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia

2024-08-08accesswire.com

Omega Pacific Intersects Three Separate Gold Zones Demonstrating Bulk-Tonnage Gold Mineralization at its Williams Property

2024-07-09accesswire.com

Omega Pacific Provides Project Overview for its Williams Property

2024-05-30globenewswire.com

Omega Therapeutics To Participate In Two Upcoming Investor Conferences
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-06 2024-05-06 2023-11-09 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2024-11-14 16:00:32 2024-08-06 07:03:38 2024-05-06 07:06:23 2024-03-28 16:31:02 2023-11-09 07:03:11 2023-08-03 16:01:00 2023-05-04 07:09:16 2023-03-01 07:05:21 2022-11-08 16:01:31 2022-03-10 16:01:13 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
revenue 3M 2M 2M 3M 831 000 759 000 516 000 2M 595 000 144 000 0 0
costOfRevenue 0 9M 2M 66M 2M 2M 0 5M 0 1M 1M 794 000
grossProfit 3M -7M 544 000 -63M -1M -1M 516 000 -3M 595 000 -1M -1M -794 000
grossProfitRatio 1 -3.377 0.231 -1.243 -1.397 1 1
researchAndDevelopmentExpenses 13M 13M 15M 77M 16M 25M 20M 80M 21M 48M 21M 12M
generalAndAdministrativeExpenses 6M 6M 7M 26M 8M 6M 6M 22M 5M 17M 6M 4M
sellingAndMarketingExpenses 0 0 -2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 6M 6M 26M 8M 6M 6M 22M 5M 17M 6M 4M
otherExpenses 0 0 -9000 0 -29 000 196 000 412 000 3M 712 000 2M 1M 1M
operatingExpenses 19M 19M 21M 103M 24M 32M 26M 105M 27M 66M 29M 17M
costAndExpenses 19M 19M 23M 103M 24M 32M 26M 105M 27M 66M 29M 17M
interestIncome 14 000 299 000 331 000 3M 684 000 957 000 0 222 000 0 0 777 000 595 000
interestExpense 0 0 0 0 684 000 957 000 682 000 0 184 000 910 000 777 000 595 000
depreciationAndAmortization 0 613 000 2M 7M 2M 2M 1M 5M 394 000 1M 1M 794 000
ebitda -16M -16M -19M -93M -23M -29M -26M -98M -26M -65M -27M -17M
ebitdaratio -6.286 -7.482 -7.896 -27.561 -38.236 -50.035 -43.01
operatingIncome -16M -17M -20M -100M -23M -31M -26M -103M -26M -66M -29M -17M
operatingIncomeRatio -6.286 -7.769 -8.666 -27.561 -40.632 -50.035 -43.672
totalOtherIncomeExpensesNet -24 000 275 000 322 000 3M 655 000 196 000 539 000 65 000 186 000 -2M -802 000 -606 000
incomeBeforeTax -16M -16M -20M -97M -22M -30M -25M -103M -26M -68M -29M -18M
incomeBeforeTaxRatio -6.296 -7.641 -8.529 -26.773 -39.113 -48.99 -43.36
incomeTaxExpense 0 0 2M 0 -2M -957 000 -1M 0 -186 000 0 0 0
netIncome -16M -16M -20M -97M -22M -30M -24M -103M -26M -69M -30M -19M
netIncomeRatio -6.296 -7.641 -8.529 -26.773 -39.113 -46.624 -43.047
eps -0.3 -0.3 -0.36 -1.8 -0.4 -0.54 -0.48 -2.14 -0.54 -1.45 -0.63 -0.39
epsdiluted -0.3 -0.3 -0.36 -0.4 -0.54 -0.48 -0.54
weightedAverageShsOut 55M 55M 55M 54M 55M 55M 51M 48M 48M 48M 48M 48M
weightedAverageShsOutDil 55M 55M 55M 54M 55M 55M 51M 48M 48M 48M 48M 48M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-01 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2023 2022 2021 2020 2019
netInterestIncome 3M 222 000 -910 000 0 0
ebit -100M -103M -66M -29M -17M
nonOperatingIncomeExcludingInterest 0 0 0 25 000 11 000
netIncomeFromContinuingOperations -97M -103M -68M -29M -18M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 -752 000 -584 000
netIncomeDeductions 0 0 0 -752 000 -584 000
bottomLineNetIncome -97M -103M -68M -29M -18M
epsDiluted -1.8 -2.14 -1.45 -0.63 -0.39

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-06 2024-05-06 2023-11-09 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2024-11-14 16:00:32 2024-08-06 07:03:38 2024-05-06 07:06:23 2024-03-28 16:31:02 2023-11-09 07:03:11 2023-08-03 16:01:00 2023-05-04 07:09:16 2023-03-01 07:05:21 2022-11-08 16:01:31 2022-03-10 16:01:13 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 30M 46M 60M 68M 82M 106M 105M 71M 77M 186M 23M 2M
shortTermInvestments 0 0 0 5M 8M 7M 32M 0 72M 39M 0 0
cashAndShortTermInvestments 30M 46M 60M 73M 89M 113M 137M 71M 148M 225M 23M 2M
netReceivables 486 000 753 000 1M 7M 1M 3M 1M 2M 1M 521 000 193 000 5000
inventory 0 0 1 303 000 11M -2M -13M 41M 0 0 0 0
otherCurrentAssets 8M 9M 10M 431 000 265 000 11M 12M 0 11M 0 0 0
totalCurrentAssets 39M 56M 71M 90M 102M 125M 137M 125M 161M 229M 24M 3M
propertyPlantEquipmentNet 114M 112M 112M 114M 115M 104M 7M 8M 8M 4M 3M 3M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 341 000 0 341 000 341 000 0 341 000 0 341 000 341 000 341 000
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 31 000 51 000 74 000 435 000 119 000 150 000 13M 13M 539 000 101 000 257 000 292 000
totalNonCurrentAssets 114M 112M 113M 114M 116M 104M 20M 21M 9M 4M 4M 3M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 153M 168M 184M 204M 218M 229M 156M 146M 170M 233M 28M 6M
accountPayables 1M 2M 2M 2M 2M 6M 4M 3M 3M 2M 1M 917 000
shortTermDebt 16M 28M 16M 4M 17M 20M 7M 5M 2M 0 3M 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 -9M 2M 0 8M 7M 0 0 0 0 3M 0
otherCurrentLiabilities 7M -4M 5M 6M 300 000 616 000 7M 8M 11M 294 000 165 000 165 000
totalCurrentLiabilities 24M 26M 25M 27M 27M 34M 18M 22M 15M 12M 8M 2M
longTermDebt 112M 111M 14M 15M 115M 99M 15M 17M 21M 20M 9M 12M
deferredRevenueNonCurrent 0 0 4M 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 98M 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 5M 5M 2M 6M 340 000 340 000 340 000 340 000 18M 853 000 76M 28M
totalNonCurrentLiabilities 117M 116M 118M 120M 115M 99M 15M 18M 22M 21M 85M 40M
otherLiabilities 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 113M 110M 98M 110M 111M 99M 2M 3M 3M 0 0 0
totalLiabilities 141M 142M 142M 146M 142M 133M 33M 40M 36M 33M 93M 42M
preferredStock 0 0 0 0 0 0 0 0 0 0 75M 27M
commonStock 55 000 55 000 55 000 55 000 55 000 55 000 55 000 48 000 48 000 48 000 5000 5000
retainedEarnings -388M -371M -355M -335M -314M -292M -262M -237M -206M -135M -66M -37M
accumulatedOtherComprehensiveIncomeLoss 0 0 -0 -14 000 -86 000 -171 000 -228 000 -479 000 -917 000 -62 000 -75M -27M
othertotalStockholdersEquity 399M 397M 396M 390M 388M 386M 341M
totalStockholdersEquity 12M 26M 41M 58M 76M 96M 123M 106M 134M 201M -65M -36M
totalEquity 12M 26M 41M 58M 76M 96M 123M 106M 134M 201M -65M -36M
totalLiabilitiesAndStockholdersEquity 153M 168M 184M 218M 229M 156M 170M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 153M 168M 184M 204M 218M 229M 156M 146M 170M 233M 28M 6M
totalInvestments 0 0 341 000 5M 8M 7M 32M 341 000 72M 39M 341 000 341 000
totalDebt 128M 127M 128M 128M 131M 119M 22M 24M 23M 20M 12M 12M
netDebt 98M 81M 68M 60M 49M 13M -82M -47M -54M -167M -11M 10M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-01 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2023 2022 2021 2020 2019
accountsReceivables 5M 0 257 000 0 0
otherReceivables 2M 2M 264 000 193 000 5000
prepaids 9M 11M 3M 859 000 375 000
totalPayables 2M 3M 2M 1M 917 000
otherPayables 0 0 0 0 0
accruedExpenses 3M 4M 10M 3M 1M
capitalLeaseObligationsCurrent 11M 2M 0 0 0
capitalLeaseObligationsNonCurrent 98M 1M 0 0 0
treasuryStock 0 0 0 74M 26M
additionalPaidInCapital 393M 344M 335M 2M 843 000
otherTotalStockholdersEquity 0 0 0 75M 27M

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA OMGA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-06 2024-05-06 2023-11-09 2023-08-03 2023-05-04 2022-11-08
acceptedDate 2024-11-14 16:00:32 2024-08-06 07:03:38 2024-05-06 07:06:23 2024-03-28 16:31:02 2023-11-09 07:03:11 2023-08-03 16:01:00 2023-05-04 07:09:16 2023-03-01 07:05:21 2022-11-08 16:01:31 2022-03-10 16:01:13 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -16M -16M -20M -97M -22M -30M -25M -103M -26M -68M -29M -18M
depreciationAndAmortization 3M 613 000 2M 7M 2M 2M 1M 5M 394 000 1M 1M 794 000
deferredIncomeTax 0 0 0 0 -3000 -456 000 0 0 0 1M 25 000 -3000
stockBasedCompensation 2M 1M 3M 9M 2M 2M 2M 8M 2M 3M 637 000 335 000
changeInWorkingCapital -2M 2M 3M -9M -5M 3M -6M -10M -3M 5M 2M 1M
accountsReceivables 206 000 457 000 5M -6M 804 000 -726 000 143 000 -362 000 -47 000 -257 000 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -285 000 135 000 -36 000 -1M -4M 3M 156 000 985 000 -88 000 1M 138 000 671 000
otherWorkingCapital -2M 1M -2M -2M -2M 534 000 -299 000 -11M -2M 4M 1M 510 000
otherNonCashItems 13 000 12 000 2M -280 000 23 000 11 000 109 000 1M 1M 106 000 -59 000 -41 000
netCashProvidedByOperatingActivities -14M -13M -12M -92M -23M -23M -28M -99M -25M -58M -26M -16M
investmentsInPropertyPlantAndEquipment -16 000 -396 000 -535 000 -3M -724 000 -1M 0 -1M -328 000 -1M -2M -885 000
acquisitionsNet 0 0 0 0 0 0 0 17M 0 0 0 0
purchasesOfInvestments 0 0 0 -20M 0 0 -20M -57M 0 -39M 0 0
salesMaturitiesOfInvestments 0 0 5M 70M 0 25M 42M 41M 11M 0 0 0
otherInvestingActivites 0 0 5M 0 0 0 0
netCashUsedForInvestingActivites -16 000 -396 000 4M -724 000 24M 22M 11M
debtRepayment -1M -1M -1M 0 0 0 0
commonStockIssued 2000 0 22 000 7000 219 000 40M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 2000 0 -1 000 000 -15 000 0 -13 000 4000
netCashUsedProvidedByFinancingActivities -1M -1M -1M -8000 219 000 40M 4000
effectOfForexChangesOnCash 0 0 0 0 26M 1M 0 0 0 0 0 0
netChangeInCash -15M -14M -8M -2M -24M 996 000 34M -116M -14M 164M 21M -5M
cashAtEndOfPeriod 31M 46M 60M 69M 82M 106M 105M 71M 77M 187M 23M 3M
cashAtBeginningOfPeriod 46M 60M 68M 71M 106M 105M 71M 187M 91M 23M 3M 7M
operatingCashFlow -14M -13M -12M -92M -23M -23M -28M -99M -25M -58M -26M -16M
capitalExpenditure -16 000 -396 000 -535 000 -3M -724 000 -1M 0 -1M -328 000 -1M -2M -885 000
freeCashFlow -14M -13M -12M -94M -24M -24M -28M -100M -25M -59M -28M -17M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-01 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2023 2022 2021 2020 2019
otherInvestingActivities 650 000 -17M -39M 0 0
netCashProvidedByInvestingActivities 48M -18M -40M -2M -885 000
netDebtIssuance 2M 0 8M 0 4M
longTermNetDebtIssuance 2M 0 8M 0 4M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 40M 0 257M 49M 8M
netCommonStockIssuance 40M 0 131M 0 0
commonStockIssuance 40M 708 000 131M 49M 8M
netPreferredStockIssuance 0 0 126M 49M 8M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 200 000 708 000 -3M 18 000 -15 000
netCashProvidedByFinancingActivities 42M 708 000 262M 49M 12M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2024-11-14 16:00 ET
Omega Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Omega Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-06 07:03 ET
Omega Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-06 07:02 ET
Omega Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-06 07:02 ET
Omega Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Omega Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-06 07:06 ET
Omega Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-06 07:04 ET
Omega Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-06 07:04 ET
Omega Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-05-06 00:00 ET
Omega Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-28 16:31 ET
Omega Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-28 16:15 ET
Omega Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-03-28 16:15 ET
Omega Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Omega Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-09 07:03 ET
Omega Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-09 07:03 ET
Omega Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Omega Therapeutics, Inc. reported for 2023 q3
SEC form 6
2023-08-03 17:13 ET
Omega Therapeutics, Inc. published news for 2023 q2
SEC form 10
2023-08-03 16:01 ET
Omega Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Omega Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-13 16:00 ET
Omega Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-12 16:15 ET
Omega Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-07-12 16:01 ET
Omega Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-12 16:02 ET
Omega Therapeutics, Inc. published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Omega Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Omega Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-03-24 16:59 ET
Omega Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-01 07:07 ET
Omega Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-01 07:05 ET
Omega Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-02-23 07:09 ET
Omega Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-11-08 16:04 ET
Omega Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-08 16:01 ET
Omega Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-10-12 07:03 ET
Omega Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-09-01 16:25 ET
Omega Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-09-01 16:14 ET
Omega Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-04 07:05 ET
Omega Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-04 07:03 ET
Omega Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-06-09 16:00 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-06-02 18:49 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-04 16:40 ET
Omega Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-04 16:10 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Omega Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-29 07:31 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-28 17:18 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-01 16:15 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-01 16:15 ET
Omega Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-10 16:01 ET
Omega Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-10 07:09 ET
Omega Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-06 16:15 ET
Omega Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-12-21 16:00 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:13 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-10 07:07 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-08 07:13 ET
Omega Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-09-10 07:19 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-09-10 07:08 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-09-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-09-10 00:00 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-03 17:21 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:04 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:04 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:04 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:03 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:02 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:02 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:01 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:01 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:01 ET
Omega Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-29 21:00 ET
Omega Therapeutics, Inc. published news for 2021 q2